Investigational drug · Phase 2
JS207
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
18
Any phase or sponsor naming "JS207"
First trial start
2025
Jul 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JS207", any sponsor or status.
- Phase 215
Conditions studied
As listed on its trial records.
- Solid Tumor
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JS207" as an intervention, largest first.
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07309276 · 864 participants (planned) · Start Jan 23, 2026 · Primary completion Nov 30, 2027
Drug: JS212 for Injection; JS207 for Injection and 2 more · For: Advanced Lung Cancer
Sites: Shanghai, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerPivotal-lookingNot yet recruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07823348 · 560 participants (planned) · Start Oct 8, 2026 · Primary completion Oct 30, 2029
Drug: JS207; JS007 and 2 more · For: Hepatocellular Carcinoma
Sites: Harbin, China; Shanghai, China
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07480733 · 410 participants (planned) · Start Apr 23, 2026 · Primary completion Nov 30, 2027
Drug: JS212 for Injection; JS213 for Injection and 2 more · For: Advanced Malignant Solid Tumors
Sites: Beijing, China
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT07466160 · 280 participants (planned) · Start Feb 11, 2026 · Primary completion Dec 31, 2027
Drug: 7MW3711; JS207 and 2 more · For: Solid Tumor
Sites: Shanghai, China
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)Pivotal-lookingRecruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07876557 · 184 participants (planned) · Start Oct 22, 2026 · Primary completion Dec 31, 2027
Drug: JS212 in combination with JS207; JS212 monotherapy and 1 more · For: Triple-negative Breast Cancer
Sites: Beijing, China; Fuzhou, China; Lanzhou, China · 31 sites in all
- The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT06022250 · 98 participants · Start Sep 26, 2023 · Primary completion Apr 8, 2026
Drug: JS207 · For: Advanced Malignant Tumor
Sites: Jinan, China
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid TumorsRecruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.Industry
NCT06953323 · 86 participants (planned) · Start Jul 10, 2025 · Primary completion Jun 30, 2029
Drug: WJB001 Capsules+Paclitaxel/Paclitaxel-albumin; WJB001 Capsules+carboplatin/Nedaplatin and 5 more · For: Advanced Solid Tumor
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 10 sites in all
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07045311 · 80 participants (planned) · Start Sep 17, 2025 · Primary completion Mar 22, 2028
Drug: JS207 in combination with 9MW2821; JS207 in combination with Albumin paclitaxel · For: Triple-negative Breast Cancer
Sites: Hefei, China; Beijing, China; Guangzhou, China · 22 sites in all
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07503756 · 80 participants (planned) · Start Apr 25, 2026 · Primary completion Dec 30, 2027
Drug: JS212; Capecitabine and 3 more · For: Metastatic Colorectal Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Optimization of Chelator Conjugation to PD-1/VEGF Bispecific Antibody for 89Zr-ImmunoPET Imaging.
Jiang Y, Hou X, Hao S, et al. · J Med Chem 2026
- Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA.
Lin S, Hong M, Zhang J, et al. · Front Immunol 2025
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.